Paraoxonases (PON) 1, 2, and 3 Polymorphisms and PON-1 Activities in Patients with Sickle Cell Disease

Imagem de Miniatura
Arquivos
art_REICHERT_Paraoxonases_PON_1_2_and_3_Polymorphisms_and_2019.PDF (427.03 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
MACEDO, Carolina Garcia de
MONTEIRO, Andreia Moreira
GIDLUND, Magnus
Citação
ANTIOXIDANTS, v.8, n.8, article ID 252, 13p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
(1) Background: Oxidative stress, chronic inflammation, vasoocclusion, and free iron are all features present in sickle cell disease. Paraoxonases (PON) are a family (PON-1, PON-2, PON-3) of antioxidant enzymes with anti-inflammatory action. Here, for the first time, we described PON-1 activities and PON-1, PON-2, PON-3 polymorphisms in patients with sickle cell disease, homozygous for HbSS, compared with healthy controls. (2) Methods: The groups were matched for age and gender. PON-1 activities (arylesterase and paraoxonase) were determined by enzymatic hydrolysis of phenylcetate and paraoxon, respectively. Polymorphisms were determined by Restriction Fragment Length Polymorphism- Polymerase Chain Reaction (RFLP-PCR). (3) Results: Plasma cholesterol and fractions, ApoA1 and ApoB levels were all decreased in sickle cell disease patients, while anti-oxidized low-density lipoprotein (LDL) antibodies and C-reactive protein were increased. Serum arylesterase activity was lower in sickle cell disease patients when compared with healthy controls. In patients, paraoxonase activity was higher in those with PON-1 RR Q192R polymorphism. In these patients, the increase of serum iron and ferritin levels and transferrin saturation were less pronounced than those observed in patients with QQ or QR polymorphism. No differences were observed with PON-1 L55M, and PON-2 and PON-3 polymorphisms. Multivariate regression analysis showed that transferrin and ferritin concentrations correlated with arylesterase and paraoxonase activities. (4) Conclusions: Both transferrin and ferritin were the main predictors of decreased arylesterase and paraoxonase activities in patients with sickle cell disease. LDL oxidation increased, and RR PON-1 Q192R polymorphism is likely to be a protective factor against oxidative damage in these patients.
Palavras-chave
paraoxonase, sickle cell disease, PON-1, ferritin, transferrin, polymorphism, oxidized cholesterol
URI
https://observatorio.fm.usp.br/handle/OPI/33402
Referências
  1. Agachan B, 2004, CELL BIOCHEM FUNCT, V22, P163, DOI 10.1002/cbf.1070
  2. Altenhofer S, 2010, J BIOL CHEM, V285, P24398, DOI 10.1074/jbc.M110.118604
  3. Atar A, 2016, RENAL FAILURE, V38, P378, DOI 10.3109/0886022X.2015.1136872
  4. Bagchi D., 2012, OBESITY, V6, P193
  5. Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1053/shem.2001.20142
  6. Bayrak A, 2016, CHEM-BIOL INTERACT, V257, P141, DOI 10.1016/j.cbi.2016.08.007
  7. Brandao SA, 2010, AM J HYPERTENS, V23, P208, DOI 10.1038/ajh.2009.214
  8. Brissot P, 2012, BBA-GEN SUBJECTS, V1820, P403, DOI 10.1016/j.bbagen.2011.07.014
  9. Cakmak A, 2009, J PEDIAT HEMATOL ONC, V31, P583, DOI 10.1097/MPH.0b013e3181acd93d
  10. Calvieri C, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7070083
  11. Camps J, 2017, CLIN BIOCHEM, V50, P804, DOI 10.1016/j.clinbiochem.2017.04.016
  12. Camps J, 2016, CHEM-BIOL INTERACT, V259, P382, DOI 10.1016/j.cbi.2016.04.005
  13. Chirico EN, 2012, IUBMB LIFE, V64, P72, DOI 10.1002/iub.584
  14. da Guarda CC, 2017, EXPERT REV HEMATOL, V10, P533, DOI 10.1080/17474086.2017.1327809
  15. dos Santos TED, 2012, BIOMARK MED, V6, P813, DOI [10.2217/BMM.12.71, 10.2217/bmm.12.71]
  16. Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200
  17. Del Giudice R, 2018, BIOMETALS, V31, P551, DOI 10.1007/s10534-018-0101-y
  18. Di Pietro N, 2016, VASC PHARMACOL, V84, P1, DOI 10.1016/j.vph.2016.05.013
  19. Fernvik EC, 2004, J CLIN IMMUNOL, V24, P170, DOI 10.1023/B:JOCI.0000019782.67993.0b
  20. Maselli LMF, 2014, DIS MARKERS, P1, DOI 10.1155/2014/480201
  21. Furlong CE, 2016, CHEM-BIOL INTERACT, V259, P51, DOI 10.1016/j.cbi.2016.05.036
  22. Gaidukov L, 2006, J LIPID RES, V47, P2492, DOI 10.1194/jlr.M600297-JLR200
  23. Gardner K, 2014, BLOOD, V123, P2302, DOI 10.1182/blood-2013-12-542076
  24. Gladwin MT, 2016, LANCET, V387, P2565, DOI 10.1016/S0140-6736(16)00647-4
  25. Gradinaru D, 2015, MECH AGEING DEV, V151, P101, DOI 10.1016/j.mad.2015.03.003
  26. Hammoudi Nadjib, 2019, Eur Heart J, DOI 10.1093/eurheartj/ehz217
  27. Hegele RA, 1997, J CLIN ENDOCR METAB, V82, P3373, DOI 10.1210/jc.82.10.3373
  28. Ikeda K, 2011, NEURODEGENER DIS, V8, P252, DOI 10.1159/000323265
  29. Kato GJ, 2013, BLOOD, V122, P1091, DOI 10.1182/blood-2013-05-505016
  30. Kotani K, 2012, J INT MED RES, V40, P1513, DOI 10.1177/147323001204000431
  31. LADU BN, 1988, AM J HUM GENET, V43, P227
  32. Levy D, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050118
  33. Loued S, 2012, LIFE SCI, V90, P82, DOI 10.1016/j.lfs.2011.10.018
  34. Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007
  35. Martinelli N, 2013, J LIPID RES, V54, P1484, DOI 10.1194/jlr.P028977
  36. Matusiewicz M, 2017, BIOMED RES INT, DOI 10.1155/2017/9541370
  37. Menini T, 2014, REDOX REP, V19, P49, DOI 10.1179/1351000213Y.0000000071
  38. Miesbach W, 2010, THROMB RES, V126, pE428, DOI 10.1016/j.thromres.2010.09.004
  39. MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
  40. Motti C, 2001, ATHEROSCLEROSIS, V158, P35, DOI 10.1016/S0021-9150(00)00765-6
  41. Nur E, 2011, AM J HEMATOL, V86, P484, DOI 10.1002/ajh.22012
  42. Okuturlar Y, 2016, RENAL FAILURE, V38, P781, DOI 10.3109/0886022X.2016.1162080
  43. Rajkovic MG, 2011, BIOCHEM MEDICA, V21, P122
  44. Reichert C.O., 2018, CURRENT TOPICS ANEMI, V1, P1
  45. Reichert CO, 2017, ACTA HAEMATOL-BASEL, V137, P220, DOI 10.1159/000471838
  46. Samir K., 2018, BLOOD, V120, P3647
  47. Senti M, 2003, EUR J INTERN MED, V14, P178, DOI 10.1016/S0953-6205(03)00041-4
  48. Singh S, 2011, TOXICOL APPL PHARM, V252, P130, DOI 10.1016/j.taap.2011.01.014
  49. Tiainen S, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7100144
  50. Valko M, 2016, ARCH TOXICOL, V90, P1, DOI 10.1007/s00204-015-1579-5
  51. van Beers EJ, 2018, CLIN HEMORHEOL MICRO, V68, P239, DOI 10.3233/CH-189010
  52. Viktorinova A, 2018, DIABETES RES CLIN PR, V140, P174, DOI 10.1016/j.diabres.2018.03.055
  53. Voskou S, 2015, REDOX BIOL, V6, P226, DOI 10.1016/j.redox.2015.07.018
  54. Wood JC, 2014, HEMATOL-AM SOC HEMAT, P210, DOI 10.1182/asheducation-2014.1.210
  55. Zohaib M, 2016, J CLIN PHARMACOL, V56, P869, DOI 10.1002/jcph.675

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/60